Pfizer's Q2 earnings came in better than expected. Revenue grew 3% to $15 billion, beating the $14.4 billion estimate. Adjusted EPS was $0.77, which also beat the $0.68 expected. They raised the lower end of their full-year revenue guidance, now projecting between $60.5 billion and $62.5 billion. EPS guidance stayed the same at $2.80 to $3.00. Their blood thinner Eliquis was a big driver, with sales up 19% from last year. That drug is hitting a patent cliff soon, so Pfizer has been leaning into acquisitions to build up their pipeline and offset future generic competition. On the regulatory side, the EU validated their application for a new Lyme disease treatment, and the FDA approved their updated COVID vaccine. The stock went up 14% last month on all this news.